

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 018781-005710US  
Client Reference No.: T00-007-1

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On 7/11/03

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Handi



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Michelle BROWNER *et al.*

Application No.: 10/004,287

Filed: October 23, 2001

For: ANTIINFLAMMATION AGENTS

Examiner: Balasubramanian, V.

Art Unit: 1624

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

MAR 09 2004

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.


It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or  
Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please  
deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
William B. Kezer  
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895

WBK:ath



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 2

Complete If Known

|                        |                      |
|------------------------|----------------------|
| Application Number     | 10/004,287           |
| Filing Date            | October 23, 2001     |
| First Named Inventor   | Browner, Michelle F. |
| Art Unit               | 1624                 |
| Examiner Name          | Balasubramanian, V.  |
| Attorney Docket Number | 018781-005710US      |

**U.S. PATENT DOCUMENTS**

| Examiner | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|----------|-----------------------|--|--------------------------------|--|---|
|          |                       | Number Kind Code <sup>2</sup> (if known) |                                |  |   |
|          | AA                    | US-6,207,679 B1                          | 03/27/2001                     | Cuny et al.  |   |
|          | AB                    | US-6,258,822                             | 07/10/2001                     | Geyer et al.                                       |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document      |                     |                                      | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>3</sup>           |
|-----------------------|--------------------------|------------------------------|---------------------|--------------------------------------|--------------------------------|---|--|--------------------------|
|                       |                          | Country<br>Code <sup>2</sup> | Number <sup>4</sup> | Kind Code <sup>5</sup> (if<br>known) |                                |   |  |                          |
|                       | AC                       | WO                           | 01/00610            | A1                                   | 01/04/2001                     | Aventis Pharma<br>Deutschland GMBH                    |  | <input type="checkbox"/> |
|                       | AD                       | WO                           | 01/30774            | A1                                   | 05/03/2001                     | Aventis Pharma<br>Deutschland GMBH                    |  | <input type="checkbox"/> |
|                       | AE                       | WO                           | 01/58890            | A1                                   | 08/16/2001                     | Astrazeneca AB  |  | <input type="checkbox"/> |
|                       | AF                       | WO                           | 01/68648            | A1                                   | 09/20/2001                     | Aventis Pharma<br>Deutschland GMBH                    |  | <input type="checkbox"/> |
|                       | AG                       | WO                           | 02/24679            | A1                                   | 03/28/2002                     | Bayer<br>Aktiengesellschaft                           |  | <input type="checkbox"/> |
|                       | AH                       | WO                           | 02/28860            | A2                                   | 04/11/2002                     | Bristol-Myers Squibb<br>Company                       |  | <input type="checkbox"/> |
|                       | AI                       | WO                           | 02/30353            | A2                                   | 04/18/2002                     | SmithKline Beecham<br>Corporation                     |  | <input type="checkbox"/> |
|                       | AJ                       | WO                           | 02/30423            | A1                                   | 04/18/2002                     | SmithKline Beecham<br>Corporation                     |  | <input type="checkbox"/> |
|                       | AK                       | WO                           | 02/41843            | A2                                   | 05/30/2002                     | Tularik Inc. and<br>F. Hoffmann La Roche<br>AG        |  | <input type="checkbox"/> |
|                       | AL                       | WO                           | 02/44153            | A1                                   | 06/06/2002                     | Bayer<br>Aktiengesellschaft                           |  | <input type="checkbox"/> |
|                       | AM                       | WO                           | 02/46171            | A2                                   | 06/13/2002                     | Signal Pharmaceuticals,<br>Inc.                       |  | <input type="checkbox"/> |
|                       | AN                       | WO                           | 02/060386           | A2                                   | 08/08/2002                     | Bristol-Myers Squibb<br>Company                       |  | <input type="checkbox"/> |
|                       | AO                       | WO                           | 02/076985           | A1                                   | 10/03/2003                     | SmithKline Beecham<br>Corporation                     |  | <input type="checkbox"/> |

Examiner  
SignatureDate  
Considered


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9060892 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 2

**Complete if Known**

|                        |                      |
|------------------------|----------------------|
| Application Number     | 10/004,287           |
| Filing Date            | October 23, 2001     |
| First Named Inventor   | Browner, Michelle F. |
| Art Unit               | 1624                 |
| Examiner Name          | Balasubramanian, V.  |
| Attorney Docket Number | 018781-005710US      |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
|                        | AP                       | Karin, M., 1999, "The Beginning of the End: I $\kappa$ B Kinase (IKK) and NF- $\kappa$ B Activation," <i>The Journal of Biological Chemistry</i> 274(39):27339-27342  |                |
|                        | AQ                       | Karin, M., 1999, "How NF- $\kappa$ B is activated: the role of the I $\kappa$ B kinase (IKK) complex," <i>Oncogene</i> 18:6867-6874   |                |
|                        | AR                       | Karin and Delhase, 2000, "The I $\kappa$ B Kinase (IKK) and NF- $\kappa$ B: key elements in proinflammatory signaling," <i>Seminars in Immunology</i> 12(1):85-98 (Abstract)  |                |
|                        | AS                       | May <i>et al.</i> , 2000, "Selective inhibition of NF- $\kappa$ B activation by a peptide that blocks the interaction of NEMO with the I $\kappa$ B kinase complex," <i>Science</i> 289:1550-1554   |                |
|                        | AT                       | Rossi <i>et al.</i> , 2000, "Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I $\kappa$ B kinase," <i>Nature</i> 403:103-108   |                |
|                        | AU                       | Woronicz <i>et al.</i> , 1997, "I $\kappa$ B Kinase- $\beta$ : NF- $\kappa$ B Activation and Complex Formation with I $\kappa$ B Kinase- $\alpha$ and NIK," <i>Science</i> 278:866-870  |                |
|                        |                          |   |                |

MAR 09 2004

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9060892 v1